Evidence map›Paper›PMID 36316298›Full record

ArticleJournal of biomedical optics2022

In vivo spectroscopic evaluation of human tissue optical properties and hemodynamics during HPPH-mediated photodynamic therapy of pleural malignancies.

Ryan D Hall Morales, Yi Hong Ong, Jarod Finlay, Andreea Dimofte, Charles B Simone, Joseph S Friedberg, Theresa M Busch, Keith A Cengel, Timothy C Zhu

Open access · goldAbstract read
In one paragraph

Article in Journal of biomedical optics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ryan D Hall MoralesUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Yi Hong OngUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Jarod FinlayUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Andreea DimofteUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Charles B SimoneNew York Proton Center, New York, United States, United States.
Joseph S FriedbergTemple University Health System, Department of Surgery, Philadelphia, Pennsylvania, United States, United States.
Theresa M BuschUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Keith A CengelUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
Timothy C ZhuUniversity of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania, United States, United States.
University of Pennsylvania · USNew York Proton Center · USTemple University Health System · US

Funding

TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8M
Optimizing singlet oxygen dosimetry for photodynamic therapy (PDT)R01EB032821 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI HADFIELD, ROBERT HUGH, ZHU, TIMOTHY C. · 2022 to 2025
$2.4M
In situ PEDSy and light delivery platform for Intracavitory Photodynamic TherapyR01EB028778 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI POTASEK, MARY, ZHU, TIMOTHY C. · 2020 to 2023
$2.2M
NCI NIH HHS P01 CA087971NIBIB NIH HHS R01 EB028778NIBIB NIH HHS R01 EB032821
6 · The paper itself

Abstract

Significance: Dosimetry for photodynamic therapy is dependent on multiple parameters. Critically, in vivo tissue optical properties and hemodynamics must be determined carefully to calculate the total delivered light dose. Aim: Spectroscopic analysis of diffuse reflectance measurements of tissues taken during a clinical trial of 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a-mediated photodynamic therapy for pleural malignancies. Approach: Diffuse reflectance measurements were taken immediately before and after photodynamic therapy. Measurements were analyzed with a nonlinearly constrained multiwavelength, multi-distance algorithm to extract tissue optical properties, tissue oxygen saturation, StO2, and total hemoglobin concentration (THC). Results: A total of 25 patients were measured, 23 of which produced reliable fits for optical property extraction. For all tissue types, StO2 ranged through [24, 100]% and [22, 97]% for pre-photodynamic therapy (PDT) and post-PDT conditions, respectively. Mean THC ranged through [ 69,152 ] μM and [ 48,111 ] μM, for pre-PDT and post-PDT, respectively. Absorption coefficients, μa, ranged through [ 0.024 , 3.5 ] cm - 1 and [ 0.039 , 3 ] cm - 1 for pre-PDT and post-PDT conditions, respectively. Reduced scattering coefficients, μs', ranged through [ 1.4 , 73.4 ] cm - 1 and [ 1.2 , 64 ] cm - 1 for pre-PDT and post-PDT conditions, respectively. Conclusions: There were similar pre- and post-PDT tissue optical properties and hemodynamics. The high variability in each parameter for all tissue types emphasizes the importance of these measurements for accurate PDT dosimetry.

Indexed as

PhotochemotherapyPleural NeoplasmsChlorophyllHemodynamicsHumansPhotosensitizing AgentsTriazenes1-phenyl-3,3-dimethyltriazene2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-aChlorophyllPhotosensitizing AgentsTriazenes2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-adiffuse reflectancephotodynamic therapytissue optical properties

Identifiers

PMID36316298
PMCPMC9621284
OpenAlexW4307888748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.